Quality of Life and Patient Needs in Advanced High Grade Gliomas
NCT ID: NCT05039346
Last Updated: 2023-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
55 participants
OBSERVATIONAL
2012-02-11
2023-01-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery
NCT01417507
Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
NCT05565118
Prognostic Awareness and Patient-Physician Communication in Malignant Glioma
NCT02023346
Prospective Study on Quality of Life in Patients With Intracranial Germ Cell Tumors
NCT05124964
Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields
NCT03501134
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Specific Aims: The aim of this study is to investigate the symptoms of patients with advanced high grade glioma. Patients who failed 3rd line chemotherapy and who require at least occasional assistance will be prospectively followed and their symptoms will be prospectively assessed. Patient's caregiver will be interviewed following the death of the patient to assess clinical symptoms in the last weeks of life and around the time of death.
Methods: Patients will undergo clinical symptom assessment via questionnaire. Patients will be followed by regular semi-structured phone interviews.
Should a patient pass, four weeks following this, the patient's care giver will be interviewed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Brain Tumor
Patients who are diagnosed with a high grade glioma that is progressive and therapy resistance. Patients will have a KPS of 60 or less.
Phone interviews
Phone interviews will be used to determine the patient's quality of life, symptoms and performance status
Care Giver
Should a patient be unable to answer, the care giver will step in and provide surrogate answers.
Additionally, at four weeks following the patient's death, the patient's care giver will be interviewed by utilizing a validated questionnaire.
Phone interviews
Phone interviews will be used to determine the patient's quality of life, symptoms and performance status
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Phone interviews
Phone interviews will be used to determine the patient's quality of life, symptoms and performance status
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Tissue proven diagnosis of a high grade brain tumor
* Disease progression by MRI
* Therapy resistant tumor to 2nd line chemotherapy
* Karnofsky Performance Scale (KPS) score of 60 or less
* Patient will need to assign caregiver
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Henry Ford Health System
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tobias Walbert, MD, PhD
Co-Director Hermelin Brain Tumor Center at the Henry Ford Cancer Institute
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tobias Walbert, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Henry Ford Health System
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB 14537
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.